To date, two sEV-based clinical assays have reached the stage of clinical validation and one assay called ExoDx Prostate (IntelliScore) has been launched onto the market in United States since 2016.[136, 137] Briefly, the ClarityDxTM System (NCT03957252) is used for prostate cancer diagnosis by detecting GHSR (ghrelin receptor), PSMA (prostate-specific membrane antigen) and polysialic acid in blood-derived sEVs by micro flow cytometry. This evidence concerns the gene FOLH1 and Familial prostate cancer.